Clinical Updates in Rheumatoid ArthritisEvolving Treatment Algorithms and Expert Perspectives on Biosimilars
2016 Annual Meeting held in Washington, DC, November 11-16, 2016.
American College of Rheumatology. Released April 2016.
Hosted by the European League Against Rheumatism (EULAR) in London, England, June 14-17, 2016.
Choy E. Rheumatology (Oxford). 2012;51(suppl 5):v3-v11.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.
Helmick CG, et al. Arthritis Rheum. 2008;58(1):15-25.
Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance.
Ishchenko A, Lories RJ. Drugs Aging. 2016;33(6):387-398.
Lim DT, et al. Curr Rheumatol Rep. 2014;16(11):459. 2012;130(2):332-342.e10.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N, et al. Mod Rheumatol. 2009;19(1):12-19.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, et al. Lancet. 2013;4:381(9877):1541-1550.
Robles-Perez A, et al. Chron Respir Dis. 2016;13(1):75-81.
Smolen JS, et al. Nat Rev Rheumatol. 2012;8(4):235-243
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y, et al. Ann Rheum Dis. 2015;74(2):389-395.
Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis
Young A, et al. Rheumatology (Oxford). 2007;46(2):350-357
Clinical Updates in Rheumatoid Arthritis
Howard Blumstein, MD; Allan Gibofsky, MD, JD; Jonathan Kay, MD
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Discussions and Debates About Moderate-to-Severe Disease
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes